Company: CERO
Filing Date: 2025-05-07
Form Type: DEF 14A
Source: 0001213900-25-040263
Chunk: 43

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-07
Form: DEF 14A
Chunk 43
---
 operations. As a result, the Company may be required to liquidate or seek bankruptcy protection. Additionally, if stockholders do not approve this proposal at the Annual Meeting, the Company would have to include a proposal to approve this proposal at a subsequent meeting of stockholders. In the event that stockholder approval is not obtained at such subsequent meeting, the Company must cause additional meetings of stockholders to be held semi -annuallythereafter until such approval is obtained. The Company would bear the costs associated with including this proposal for stockholder approval at subsequent stockholder meetings. Vote Required; Board Recommendation The affirmative vote of the holders of a majority of the votes cast at the Annual Meeting will be required to approve this proposal. Abstentions and broker non -voteswill have no effect on the outcome of this proposal.

| THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE ISSUANCE OF SHARES OF COMMON STOCK, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635, UPON THE CONVERSION OF THE SERIES D PREFERRED STOCK AT AN EXERCISE PRICE BELOW THE MINIMUM PRICE. |     | ✓ |

21 PROPOSAL NO. 4: PLAN SHARE INCREASE PROPOSAL Overview On May6, 2025, the Board approved, subject to stockholder approval, Amendment No. 3 to the 2024 Plan (the “Amendment” and the 2024 Plan as so amended, the “Amended Plan”) to increase the number of shares available for issuance under the 2024 Plan and the limit on the number of shares that may be issued pursuant to incentive stock options by, in each case, 2,000,000shares of Common Stock to 2,280,180shares of Common Stock and 2,279,446shares of Common Stock, respectively. Of the resulting share reserve, approximately 2,000,000shares (no shares available for grant as of May1, 2025 plus 2,000,000shares being requested under this proposal) would be available for new awards, not including any shares that would become available again upon the expiration, termination, cancellation, cash settlement or forfeiture of certain previously -issuedawards, as described below. A copy of the Amended Plan is attached to this proxy statement as Appendix B. The compensation committee of the Board (the “compensation committee”) believes the number of shares of common stock available for issuance under the Plan is not sufficient to make the grants that will be needed